IBRX - CIK 0001326110
ImmunityBio, Inc. (IBRX) reported net income of -$351.50M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$351.50M | +15.0% |
| FY 2024 | -$413.60M | +29.2% |
| FY 2023 | -$583.90M | -39.9% |
| FY 2022 | -$417.30M | -19.3% |
| FY 2021 | -$349.80M | -57.7% |
| FY 2020 | -$221.85M | -40.6% |
| FY 2019 | -$157.78M | -64.0% |
| FY 2018 | -$96.23M | +0.2% |
| FY 2017 |
ImmunityBio, Inc. (IBRX) reported net income of -$351.50M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2013 and fiscal 2025, ImmunityBio, Inc.'s net income declined from -$2.05M to -$351.50M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$96.42M |
| +20.2% |
| FY 2016 | -$120.81M | +49.0% |
| FY 2015 | -$236.88M | -3729.8% |
| FY 2014 | -$6.18M | -202.1% |
| FY 2013 | -$2.05M | - |